Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Cord Blood America Licenses Technology to AXM Pharma in China

publication date: Apr 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Cord Blood America, Inc. has signed a deal licensing its umbilical cord blood technology to AXM Pharma, Inc., a China pharma and nutraceutical company. In addition to the license, Cord Blood America will provide consulting and training. In return, it will receive a 10% equity stake in AXM Pharma's stem cell subsidiary and an 8.5% royalty on all cord blood revenues. More details...

Stock Symbols: (OTCBB: CBAI) (OTCPK: AXMP)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners